This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.
Gill A. Webster, PhD
Advertisement
Gill A. Webster, PhD, is chief scientific officer at Virionyx Corporation Ltd.
Articles by Gill A. Webster, PhD
Advertisement
Latest Updated Articles
The Therapeutic Vaccine Potential of MIS416 AdjuvantPublished: January 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
